Latest filing published 22 May 2026 for Oncology Institute, Inc., €6,170. Read the official filing
Not enough history yet: 0 closed purchases, at least 2 are needed.
Robert Ross Carter is a declared insider of Starling Oncology, Inc., with filings sourced from SEC (Form 4). We count 13 filings; the first trade dates from 20 November 2024 and the latest from 21 May 2026.
On the open market, the record shows 1 purchase worth €8,745 and 1 sale worth €748. Taken together, the purchases exceed the sales by €7,997. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 3 share grants. Since January 2026: no purchases and 1 sale on the market.
The newest entry dates from 22 May 2026: a transaction of €6,170, in Starling Oncology, Inc. The last purchase on record was published on 28 March 2025, which is 569 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations